Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Chlorella vulgaris* is a species of unicellular green microalgae that is widely utilized as a bioactive dietary supplement and nutraceutical due to its high content of proteins, chlorophyll, carotenoids, and essential micronutrients. In clinical research, it has been investigated for its ability to modulate oxidative stress, inflammation, and metabolic pathways. Studies have evaluated its efficacy as an adjunctive treatment for major depressive disorder (MDD), where it may alleviate physical and cognitive symptoms, and for obstructive pulmonary diseases such as COPD and asthma, where it enhances systemic antioxidant capacity. Additionally, *Chlorella vulgaris* is studied for its potential to reduce markers of muscle damage (e.g., creatine kinase) following strenuous exercise and for its hypoglycemic properties in patients with type 2 diabetes, likely mediated through the activation of PPAR gamma receptors and increased glucose uptake in peripheral tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorella vulgaris.